CEOs endorse F-35, upbeat in progress

Article Abstract:

According to Lockheed Martin, the business and military leaders who are responsible for the development of the F-35 Joint Strike Fighter (JSF) are excited about the recent progress made in the project. The leaders of this project endorsed and pledged the required support in completing the trade studies, taking corrective actions and accelerating the pace, which will help in stabilizing the program and completing it before the Critical Design review in 2005.

Aircraft industry, Lockheed Martin Corp.

---

Raptor development problems could afflict JSF: Roche

Article Abstract:

Roche, the Air Force secretary noted that the JSF program, intended to provide a common aircraft for the Air Force, Navy and Marine Corps as well as the U.K. military, is only two years old but has run into delays. Roche states that the Air Force is considering several options to get back on schedule for initial operational test and evaluation, which Raptor must pass before the Pentagon can approve full-rate production.

Management dynamics, Management, Reports, Military aspects, Company business management, Air forces, Air Force officers

---

Weight coming off STOVL JSF variant

Article Abstract:

Designers have made significant weight reductions in the weight of F-35 Joint Strike Fighter (JSF) and short take-off and vertical landing (STOVL) intended for the Marine Corps. Following the decision to reduce the weight, the Pentagon has added one year and granted additional $5 billion to the development program.

Military Aircraft

Similar abstracts:

• Abstracts: Finance bill progress. Working for change
• Abstracts: Regulatory realities. Leap of faith. Hard times. Soft options
• Abstracts: Key lawmaker flails F-35 Joint Strike Fighter program.. Krieg says Osprey passed review, including key parameters
• Abstracts: Gamestec used ATEI to release new solutions. Getting sorted. Sega's two new games and one new website
• Abstracts: Europe caught in innovation quagmire. Antibodies' long revenue stream spurs pharma acquisitions. Sanofi takeover jeopardizes Aventis biotech deals

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.